CERO

CERo Therapeutics Holdings, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website -
Employees(FY) -
ISIN US71902K1051

Performance

-7.03%

+190.65%

+81.08%

-77.38%

-97.76%

YTD

-97.72%

Profile

Advanced Technical Analysis

Technical Analysis of CERO 2024-11-20

The Moving Average Score of 70 indicates a bullish sentiment, while the Oscillators Score of 46 and the Technical Score of 58 suggest a more neutral outlook. Overall, the combined scores reflect a cautiously optimistic sentiment in the stock, driven primarily by the strong moving average performance.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CERO

Stock Rank

Recent News & Updates

2024-11-14 19:45
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia(Yahoo Finance)
2024-11-10 19:15
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity(Globenewswire)
2024-10-20 21:00
CERo Therapeutics, Inc. Provides Corporate Update(Globenewswire)
2024-10-01 21:15
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer(Globenewswire)
2024-09-24 21:17
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236(Yahoo Finance)
2024-07-07 20:00
CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024(Globenewswire)
2024-06-12 20:15
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236(Globenewswire)
2024-06-05 22:15
Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy(Yahoo Finance)
2024-06-05 20:00
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236(Globenewswire)
2024-05-14 20:00
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders(Globenewswire)
2024-04-29 21:00
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes(Globenewswire)
2024-03-06 18:00
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients(Businesswire)
2024-02-14 03:48
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination(Businesswire)
2023-06-04 20:00
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics(Yahoo Finance)

Page 1 of 1

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.